Genfleet Therapeutics (Shanghai) Inc.

Genfleet Therapeutics (Shanghai) Inc. (2595.HK) is an innovative drug development company with a global footprint, focused on highly unmet clinical needs in oncology and immune-related diseases. Centered on disease biology mechanisms and clinical translational medicine, it builds on a self-driven, integrated R&D system and targets innovative targets and indications that have not yet been clinically validated, holding global independent intellectual property rights. Since its founding in 2017, the company has established multiple self-developed "global-new" large- and small-molecule programs, with several products entering global multicenter clinical trials in China, Europe and the United States, including late-stage or pivotal studies. Dabert® (fulzerasib) is the first product from Genfleet's pipeline approved for marketing in China and is described as the first KRAS G12C inhibitor approved in China and the third globally; the company has formed an integrated RAS-targeted therapy matrix covering multi-target and multi-modality selective and pan-RAS inhibitors. Genfleet has also been recognized as a national-level "little giant" specialized and sophisticated enterprise and a national high-tech enterprise, and has been certified as a Shanghai specialized and sophisticated SME, a Shanghai multinational company R&D center, and a Shanghai enterprise technology center.

Genfleet Therapeutics (Shanghai) Inc. was founded in 2017. Since then it has established multiple self-developed "global-new" large- and small-molecule programs, with several products entering global multicenter clinical trials in China, Europe and the United States, including late-stage or pivotal clinical studies. Its pipeline includes Dabert® (fulzerasib), described as the first product from the pipeline approved for marketing in China and the first KRAS G12C inhibitor approved in China and the third globally. The company has formed an integrated RAS-targeted therapy matrix spanning multi-target and multi-modality selective and pan-RAS inhibitors, and is also expanding into other "global-new" targeted drugs and first-in-class multi-type bispecific therapies. Its official company history timeline lists years from 2017 through 2026, including 2026 milestones such as the first domestic KRAS G12Di being included in NSCLC BTD in March, the first domestic KRAS G12Di monotherapy being included in pancreatic cancer BTD in April, and the launch of the company's second registrational Phase III clinical study in August; in 2025, the company's first bispecific antibody product (GFS202A) received clinical trial approval for cachexia in March, and in July the pipeline's first registration and marketing approval outside mainland China for fulzerasib.

A globally oriented innovative drug developer pursuing "global-new" targets and indications in oncology, immune and inflammatory diseases, with an integrated in-house R&D system and global independent IP.

• Dabert® (fulzerasib / GFH925)

  KRAS G12C inhibitor; the first product from Genfleet's pipeline approved for marketing in China and described as China's first and the world's third marketed KRAS G12C inhibitor. Pipeline indications include non-small cell lung cancer and combination with cetuximab for NSCLC.

• GFH375

  KRAS G12D inhibitor; pipeline programs include monotherapy for pancreatic cancer and non-small cell lung cancer, combination with GFH276 or GFS202A for PDAC, combination with chemotherapy for first-line pancreatic ductal adenocarcinoma and with cetuximab for solid tumors, and monotherapy and combination with cetuximab for pancreatic ductal adenocarcinoma.

• GFH009

  CDK9 inhibitor for acute myeloid leukemia.

• GFS202A

  GDF15/IL-6 bispecific antibody for cachexia; the company's first bispecific antibody product to receive clinical trial approval.

• GFH276

  Pan RAS (ON) inhibitor for solid tumors.

• GFS784

  ADC for solid tumors.

• 2021.12.31

  Reported2021.12.31

  GenFleet Therapeutics completes $75 million Series C financing[6]GenFleet Therapeutics完成7500万美元C轮融资prnewswire.com

  GenFleet Therapeutics announced completion of a $75 million Series C financing led by Huagai Capital, with new and existing investors participating.

• 2020.03.09

  Reported2020.03.09

  JinFang Medicine completes Series B financing[7]劲方医药完成B轮融资tech.sina.com.cn

  JinFang Medicine announced that it had completed a Series B financing of nearly RMB 400 million, co-led by CDH Investments and Shenzhen Capital Group's healthcare fund, with other investors participating and existing investors increasing their investment.

Read more

1. 1劲方医药_首页genfleet.com
2. 2深度布局肿瘤、免疫、炎症类疾病领域创新疗法，聚焦"全球新"靶点及适应症-劲方医药_首页genfleet.com
3. 3公司简介-致力于"全球新"药物开发，深耕RAS疗法赛道、放眼多元创新疗法-劲方医药_首页genfleet.com
4. 4真诚、平等、尊重；在劲方，大家拥有同一个目标，同一个梦想-劲方医药_首页genfleet.com
5. 5Genfleet Therapeutics (Shanghai) Inc. (China)wikidata.org
6. 6GenFleet Therapeutics完成7500万美元C轮融资prnewswire.com
7. 7劲方医药完成B轮融资tech.sina.com.cn